Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons

References

• Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-81
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:2574-609
   PubMed Web of Science ®Google Scholar
• Cowley MJ, Kuritzky L. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Curr Med Res Opin 2009;25:1477-90
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis. Int J Cardiol 2008;128:166-71
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-23
   PubMed Web of Science ®Google Scholar
• Panchal HB, Shah T, Patel P, et al. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis. J Cardiovasc Pharmacol Ther 2013 Jul 19
   Google Scholar
• Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010;159:284-91 e1
   PubMed Web of Science ®Google Scholar
• Porto I, D'Amario D, Crea F. Cilostazol and primary-PCI: mirage or good alternative? Curr Vasc Pharmacol 2012;10:468-71
   PubMed Web of Science ®Google Scholar
• Watson A, Mikhailidis DP, Stansby G. Cilostazol for peripheral arterial disease could reduce stroke risk? Thromb Res 2013;132:149-50
   PubMed Web of Science ®Google Scholar
• Dinicolantonio JJ, Lavie CJ, Fares H, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013;112:1230--4
   Google Scholar
• Maruyama H, Fukuoka T, Deguchi I, et al. Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke. Intern Med (Tokyo, Japan) 2013;52:1043-7
   PubMed Web of Science ®Google Scholar
• Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013;127:2307-15
   PubMed Web of Science ®Google Scholar
• Zhang Z, Foster JK, Kolm P, et al. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 2006;152:770-6
   PubMed Web of Science ®Google Scholar
• Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-8
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007;71:1867-72
   PubMed Web of Science ®Google Scholar
• Min PK, Jung JH, Ko YG, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007;71:1685-90
   PubMed Web of Science ®Google Scholar
• Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32
   PubMed Web of Science ®Google Scholar
• Lee SW, Ahn JM, Han S, et al. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). Am J Cardiol 2013 Jul 23
   Google Scholar
• Takagi H, Umemoto T. A meta-analysis of randomized trials of triple versus dual antiplatelet therapy after stent-based percutaneous coronary intervention. Int J Cardiol 2011;150:228-30
   PubMed Web of Science ®Google Scholar
• Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009;5:384-93
   PubMed Web of Science ®Google Scholar
• Jang JS, Jin HY, Seo JS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 2012;122:133-43
   PubMed Web of Science ®Google Scholar
• Friedland SN, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 2012;109:1397-404
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
   PubMed Web of Science ®Google Scholar
• Members ATF, Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (Clinical Research Ed) 2003;326:472--5
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011;150:325-31
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2013. Available at: handbook.cochrane.org [last accessed July 2013]
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed) 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997;315:629-34
   PubMed Web of Science ®Google Scholar
• Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-80
   PubMed Web of Science ®Google Scholar
• Wang SL, Sun F, Zhao X, et al. [Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction]. Zhonghua xin xue guan bing za zhi 2010;38:870-4
   PubMedGoogle Scholar
• Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280-9
   PubMed Web of Science ®Google Scholar
• Park SJ. L-D-ISI. Percutaneous treatment of LONG native coronary lesions with drug-eluting stent-II: cypher versus taxus, LONG-DES-II. 2011. Available at: http://www.crtonline.org/flash.aspx?PAGE_ID=33972012 [Last accessed July 2013]
   Google Scholar
• Lu YL, Chen YD, Lu SZ. [Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention]. Zhonghua xin xue guan bing za zhi 2007;35:793-6
   PubMedGoogle Scholar
• Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011;57:1264-70
   PubMed Web of Science ®Google Scholar
• Lee SW, Chun KJ, Park SW, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010;105:168-73
   PubMed Web of Science ®Google Scholar
• Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9
   PubMed Web of Science ®Google Scholar
• Gao W, Zhang Q, Ge H, et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology 2013: published online 27 January 2013, doi: 10.1177/0003319712474113
   Google Scholar
• Chen YD, Lu YL, Jin ZN, et al. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J 2006;119:360-6
   PubMed Web of Science ®Google Scholar
• Ahn CM, Hong SJ, Park JH, et al. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2011;26:502-10
   PubMed Web of Science ®Google Scholar
• Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012;8:CD002071
   PubMedGoogle Scholar
• Takigawa T, Tsurushima H, Suzuki K, et al. Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. J Vasc Surg 2012;55:506-16
   PubMed Web of Science ®Google Scholar
• Rizzo M, Corrado E, Patti AM, et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011;12:647-55
   PubMed Web of Science ®Google Scholar
• Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000;35(1 Pt 2):237-43
   Web of Science ®Google Scholar
• Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atherosclerosis Supplements 2005;6:41-6
   PubMed Web of Science ®Google Scholar
• Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004;44:1408-14
   PubMed Web of Science ®Google Scholar
• Sanganalmath SK, Barta J, Takeda N, et al. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 2008;86:180-9
   PubMed Web of Science ®Google Scholar
• Sanganalmath SK, Babick AP, Barta J, et al. Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure. J Cell Mol Med 2008;12:1728-38
   PubMed Web of Science ®Google Scholar
• Wouter Jukema J, Collet JP, De Luca L. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Curr Med Res Opin 2012;28:203-11
   PubMed Web of Science ®Google Scholar
• Yang TH, Jin HY, Choi KN, et al. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. Int J Cardiol 2012: published online 26 October 2012, doi: 10.1016/j.ijcard.2012.09.093
   Google Scholar